ACC CardiaCast

This podcast discusses the risks and benefits of starting new diabetes therapies on a patient with type 2 diabetes. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the cardioprotective effects of new drug classes will prepare you to better treat your patients.

This podcast discusses monitoring patients who have been started on a new diabetes therapy, such as sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide 1 receptor agonists. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the cardioprotective effects of new drug classes will prepare you to better treat your patients.

This podcast discusses the article "Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis." As the incidence of type 2 diabetes mellitus rises in the United States, understanding the cardioprotective effects of new drug classes will prepare you to better treat your patients. Learn how the classification of diabetes mellitus has changed from describing a homogenous group to a heterogeneous group and how that affects treatment.

This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.

This podcast discusses controversies in lipid management, including the safety of very low low-density lipoprotein cholesterol levels, the role of PCSK9 in high-risk patients for primary prevention, and the use of formal risk assessment and imaging in primary prevention.

This podcast discusses new data pertaining to glucagon-like peptide-1 receptor agonists in the treatment of diabetes and their cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the ELIXA trial (Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 [Lixisenatide]) will prepare you to better treat your patients.

This podcast discusses the importance of the patient to the care team, particularly regarding medication adherence, and considers the roles of the pharmacists, nurse practitioners, and physician assistants as well as the physician.

This podcast discusses the top 10 things you should remember from the ACC Focused Update on Non-Statin Therapies For LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: Expert Consensus Decision Pathway.